Boston Aphasia Severity Rating Scale
Boston Diagnostic Aphasia Examination Severity Rating Scale (BDAE-SRS) · Also known as: BDAE, Boston Aphasia Rating Scale, Boston Aphasia Severity
The Boston Diagnostic Aphasia Examination Severity Rating Scale (BDAE-SRS) is the gold-standard clinician-administered assessment of aphasia severity and type in adults following stroke or acquired brain injury. Developed by Goodglass, Kaplan, and colleagues (2001, third edition), BDAE provides comprehensive evaluation of language across 18 domains (auditory comprehension, oral expression, naming, repetition, reading, writing) and yields both an overall severity rating (0–5 scale) and a detailed profile classifying aphasia syndrome (Broca's, Wernicke's, conduction, global, etc.). BDAE is foundational to aphasia diagnosis, prognosis, and treatment planning.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
BDAE is the standard assessment for any adult presenting with aphasia (post-stroke, traumatic brain injury, progressive neurological disease) to establish baseline language function, classify aphasia type, determine severity, and guide differential diagnosis. Administer at initial evaluation (typically 3–7 days post-stroke when acute confusion resolves but before major spontaneous recovery occurs). Repeat BDAE at 4–6 weeks, 3 months, and 6 months post-stroke to document recovery trajectory and treatment response. Administer BDAE-Short Form or BDAE-Severity Rating alone at frequent intervals (weekly) if full BDAE is too time-consuming for clinical monitoring. BDAE is also valuable in research comparing aphasia rehabilitation approaches, in prognostic studies predicting long-term recovery, and in diagnosis of primary progressive aphasia (PPA) where aphasia severity and type evolve over time. Less suitable for mass screening (too lengthy) or for patients in acute confusion or coma; use simpler tools (National Institutes of Health Stroke Scale language items) in emergency/acute settings.
Strengths & limitations
- Gold-standard, comprehensive aphasia assessment: BDAE is the most widely used aphasia battery globally; extensively researched with strong psychometric properties (inter-rater reliability ICC 0.85–0.95 across subtests); teaches clinicians systematic approach to language assessment; results are understood across settings (inpatient, outpatient, research).
- Detailed linguistic profile revealing aphasia syndrome and type: 18 subtests across modalities enable classification of Broca's, Wernicke's, conduction, anomic, global, and transcortical aphasias with clinical precision; pattern of preserved vs. impaired abilities guides differential diagnosis and therapy targeting.
- Quantified severity rating with clinical interpretation: 0–5 ordinal Severity Rating directly maps to functional language status and guides prognostic conversations ('Your aphasia is mild, with good recovery expected' vs. 'Moderate-to-severe; progress may be slower').
- Sensitive to change: BDAE subtests improve during aphasia therapy and post-stroke spontaneous recovery; useful for documenting treatment efficacy and natural history trajectories in individual patients and research groups.
- Establishes baseline for comparison: initial BDAE creates benchmark for measuring recovery; subsequent administrations at standardized intervals provide objective documentation of progress or plateau.
- Lengthy administration and scoring time: full BDAE requires 45–60 minutes to administer and 30+ minutes to score and interpret; impractical for frequent clinical monitoring or in time-limited settings (ICU, emergency department); BDAE-Short Form or Brief Boston Naming Test can address this but provides less comprehensive profile.
- Requires clinician expertise and training: accurate administration, scoring, and interpretation require training in aphasia assessment; untrained clinicians may introduce administration or scoring errors; scoring rules for ambiguous responses require clinical judgment.
- Limited by patient fatigue and testing environment: lengthy testing may exceed attention tolerance in acute post-stroke phase or patients with cognitive fatigue; noise/distraction in hospital setting affects performance; fatigue effects not always recognized in single testing session.
- Subtest performance variability across repeated testing: BDAE subtest scores fluctuate day-to-day and session-to-session due to fatigue, motivation, anxiety, mood; single BDAE administration captures one time point and may not represent typical functional ability; serial assessments (3–5 occasions over weeks) required for stable estimate.
- Incomplete capture of functional communication: BDAE measures linguistic abilities (naming, repetition, comprehension) but does not directly assess functional communication effectiveness in real-world contexts (conversation, problem-solving, using AAC device); pair with functional communication measures (Communicative Activities of Daily Living, Pragmatic Protocol) for comprehensive assessment.
Frequently asked
What is the relationship between BDAE Severity Rating and prognosis for aphasia recovery?
Initial BDAE Severity combined with aphasia type predicts recovery trajectory: Mild aphasia (Rating 4) generally shows 70–90% recovery by 6 months with therapy. Moderate (Rating 2–3) shows 40–70% recovery with therapy, highly variable. Severe (Rating 0–1) shows slower, more limited recovery, with 10–40% expected at 6 months depending on type (Broca's better than global). However, prognostic factors beyond BDAE severity include: age (younger = better), time post-onset (earlier = more spontaneous recovery), aphasia type (Broca's/conduction > global), lesion size/location (smaller/less critical areas = better), co-morbidities, and motivation. BDAE alone does not determine prognosis; integrate with imaging and other clinical factors.
Can I administer BDAE-Short Form instead of full BDAE to save time?
Yes—BDAE-Short Form or abbreviated versions (15–20 minute administration) are acceptable for frequent monitoring (weekly/bi-weekly) during therapy. However, shortened versions sacrifice some diagnostic specificity (less detailed aphasia type classification) and provide less comprehensive language profile. Use full BDAE at baseline and discharge for comprehensive assessment; use shortened versions for interim monitoring. If using abbreviated version, note this in documentation so results are not over-interpreted beyond what brief assessment can provide.
How do I interpret BDAE results if performance varies widely across sessions?
Session-to-session variability is common post-stroke (fatigue, motivation, mood state). If BDAE Severity Rating differs by ≥1 point across two sessions, obtain a third session and average results for more stable estimate. Variability itself is clinically informative—if patient performs well when rested/motivated but poorly when fatigued, this suggests fatigue management and cognitive rest are important for treatment success. Document session conditions (time of day, patient alertness, pain/discomfort) to contextualize results; repeat assessments consistently at same time of day to reduce variability.
Is BDAE appropriate for elderly patients or those with dementia?
BDAE can be administered to older adults; age-based norms in BDAE manual account for normal aging. However, dementia complicates interpretation—low BDAE scores may reflect cognitive impairment (memory, attention, executive function) rather than language/aphasia. If cognitive impairment is suspected, administer cognitive screening (Montreal Cognitive Assessment, Mini-Cog) alongside BDAE; integrate results to distinguish language disorder from dementia or depression (both lower BDAE scores for reasons other than aphasia).
Sources
- Goodglass, H., Kaplan, E., & Barresi, B. (2001). The Boston Diagnostic Aphasia Examination–Third Edition (BDAE-3). Philadelphia: Lippincott Williams & Wilkins. ISBN: 978-0-683-30562-9
- Kertesz, A. (1982). Western Aphasia Battery. New York: Grune & Stratton. link ↗
- Scarpa, M. C., Colombo, M., Agosta, F., Volonté, M. A., & Filippi, M. (2009). Longitudinal Neuroimaging and Neuropsychological Changes in Primary Progressive Aphasia. Neurology, 72(8), 1705–1711. link ↗
How to cite this page
ScholarGate. (2026, June 3). Boston Diagnostic Aphasia Examination Severity Rating Scale (BDAE-SRS). ScholarGate. https://scholargate.app/en/speech-language-pathology/boston-aphasia-severity
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Aphasia Impact QuestionnaireSpeech Language Pathology↔ compare
- Communication Confidence Rating Scale for AphasiaSpeech Language Pathology↔ compare
- Voice Handicap IndexSpeech Language Pathology↔ compare